Syros Pharmaceuticals, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
SYRS on Nasdaq
Location
35 Cambridge Park Drive, Cambridge, Massachusetts

Insiders trading volume in the past year

Syros Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Nancy A. Simonian Director $1.07 M Jun 5, 2024
Jason Haas Chief Financial Officer $262 K Mar 31, 2024
Kristin Stephens Chief Development Officer $245 K Mar 31, 2024
Gerald E. Quirk Chief Legal & Compliance Offic $222 K Mar 27, 2024
Conley Chee President & CEO, Director $218 K Mar 31, 2024
Timothy Tyson Director $164 K Jun 5, 2024
David Roth Chief Medical Officer $137 K -$137 K -50.2% Apr 3, 2024
Marsha Fanucci Director $79.2 K Jun 5, 2024
Wirth Peter Director $79.2 K Jun 5, 2024
Deborah Dunsire Director $79.2 K Jun 5, 2024
Sue Gail Eckhardt Director $79.2 K Jun 5, 2024
Andrew M. Oh Director $79.2 K Jun 5, 2024
Richard A. Young Director $52.8 K -$178 K -77.2% Jun 28, 2024
Srinivas Akkaraju Director $52.8 K +$4 M Jun 5, 2024
Eric R. Olson Chief Scientific Officer $29.4 K -$2.41 K -7.57% Jul 17, 2023
Mark J. Alles Director $28 K Sep 16, 2023
Amir Nashat Director Jun 1, 2022
Phillip A. Sharp Director Jun 1, 2022

Recent Insider Transactions by Companies or Individuals for Syros Pharmaceuticals, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership